natalizumab MS
Selected indexed studies
- Natalizumab update. (Am J Health Syst Pharm, 2007) [PMID:17384355]
- Dosing interval of natalizumab in MS: Do good things come to those who wait? (Neurology, 2019) [PMID:31515289]
- Natalizumab wearing-off symptoms: Patients with MS on extended interval dosing may not "mind the gap". (Neurology, 2019) [PMID:31551259]
_Worker-drafted node — pending editorial review._
Connections
natalizumab MS is a side effect of
Sources
- Natalizumab update. (2007) pubmed
- Dosing interval of natalizumab in MS: Do good things come to those who wait? (2019) pubmed
- Natalizumab wearing-off symptoms: Patients with MS on extended interval dosing may not "mind the gap". (2019) pubmed
- Incidence of seroconversion and sero-reversion in patients with multiple sclerosis (MS) who had been treated with natalizumab: A systematic review and meta-analysis. (2020) pubmed
- Pharmacodynamics of natalizumab extended interval dosing in MS. (2020) pubmed
- Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. (2020) pubmed
- Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres. (2024) pubmed
- Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis. (2021) pubmed
- Natalizumab reduces serum pro-angiogenic activity in MS patients. (2018) pubmed
- Improvement of Comorbid Psoriasis in Patients With MS Treated With Natalizumab. (2021) pubmed